DBV技术为幼儿提供Viaskin Peanut补丁,以更快地获得林业发展局的核准。 DBV Technologies advances Viaskin Peanut patch for toddlers toward faster FDA approval.

DBV技术与美国林业发展局合作,为1至3岁幼儿的Viaskin Peanut补丁加快批准途径。 DBV Technologies has aligned with the U.S. FDA on an accelerated approval pathway for its Viaskin Peanut patch for toddlers aged 1 to 3 years. 这种批准途径是针对治疗具有有意义的优势并显示临床可能受益的严重条件。 This approval pathway is for serious conditions where the treatment offers a meaningful advantage and shows a likely clinical benefit. 该公司预计将在2026年下半年提交针对这一年龄组的生物学许可证申请(BLA)。 The company anticipates submitting its Biologics License Application (BLA) for this age group in the second half of 2026.